Compare Ginkgo Bioworks Holdings Inc (DNA) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs J M Smucker Co — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while J M Smucker Co trades at $119.83 (market cap $12.76B). The key difference: J M Smucker Co is far larger — about 16.7× Ginkgo Bioworks Holdings Inc's market cap, and J M Smucker Co pays a 3.75% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and J M Smucker Co for 74 Days on average.
| DNA | SJM | |
|---|---|---|
Market Cap | $763.64M | $12.76B |
Volume | 3,204,177 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $15.83 | $132.34 |
52-Week Low | $5.48 | $89.53 |
Typical Hold Time | 7 Days | 74 Days |
Enterprise Value | $865.59M | $19.61B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
SJM stock trades at $119.41, up 3.0% with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The company maintains strong cash flow from operations at $1.21B and recently raised FY27 EPS guidance to $10.50-$11.00. However, 2025 results showed a net loss of $1.23B despite $8.73B revenue, with elevated P/E ratio of 55.8 suggesting premium valuation.
Outlook remains cautiously optimistic with analyst consensus target of $138.23 (16% upside) and 52% buy ratings, though high debt levels and margin pressures present risks. The stock offers dividend income with upcoming $1.12 payment, while technical support at $118 provides near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
